Idorsia seeks US label update for QUVIVIQ daytime functioning benefits – first patients enrolled in Dari-Dream

What happened

Idorsia Ltd said the first patients have enrolled in Dari-Dream, a US label-enabling study of QUVIVIQ (daridorexant) 50 mg in adults and elderly people with insomnia disorder, aiming to support inclusion of daytime functioning benefits in US prescribing information.

Confirmed

Global impact / market context

A US label update could let Idorsia market QUVIVIQ on daytime functioning, not just sleep, which may support demand and revenue per prescription. The study also carries cost and timeline risk before any labeling change is granted.

Analyst inference

QUVIVIQ's daytime functioning data already appear in prescribing information in multiple countries including Europe, but not yet in the US. The US study follows discussions with the US Food and Drug Administration, so investors may weigh whether US labeling catches up with European labeling.

Analyst inference

What to watch

1. Idorsia said Dari-Dream is designed to further characterize QUVIVIQ's impact on daytime functioning and support its inclusion in US prescribing information, which is the formal drug label. Confirmed
2. Watch whether Dari-Dream results show meaningful improvement across the IDSIQ domains of alertness and cognition, mood, and sleepiness, and whether Idorsia submits a US label update. Proposed
3. Track study enrollment pace and spending, since a slow or costly trial would delay any US label change and defer potential revenue benefit from broader prescribing claims. Analyst inference

Evidence

• globenewswire.com